Alzheimer’s Patient Registry Raising Questions as Drug OK Nears

Bloomberg News, June 29, 2023: If Leqembi is approved for very early Alzheimer’s, CMS and NCHR explain how the Medicare registry will help patients make informed decisions about whether the benefits are likely to outweigh the risks for them for this expensive and risky treatment. But PhRMA and aligned patient groups complain.

Read More »

Pricey Alzheimer’s Drug Coverage Hinges on FDA Decision

Bloomberg News, June 15, 2023: If Leqembi is approved, it will take time for doctors to arrange for patients to be tested for mild cognitive impairment and amyloid plaques on the brain, get the Leqembi infusions, and sign up patients for a registry. NCHR praises the CMS Registry as a good choice, but industry-funded groups complain.

Read More »